文献速递前列腺癌

定义高危前列腺癌根治性前列腺切除术后预测总生存的最具信息量的中间临床终点

Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-12-24

研究纳入12家三级转诊中心1988至2016年间接受根治性前列腺切除加扩大盆腔淋巴结清扫的3507例高危前列腺癌患者,评估术后1、3、5、7年内生化复发和临床复发对总生存的预测价值,发现术后5年内出现临床复发预测总生存区分度最高(c指数0.74),生化复发后12个月内进展至临床复发预测后续全因死亡风险区分度最高。

要点

  • 术后5年内临床复发是预测总生存最具信息量的中间临床终点,c指数0.74。
  • 生化复发后12个月内进展至临床复发对后续全因死亡风险区分度最高。
  • 术后5年内生化复发且12个月内进展至临床复发的患者10年总生存率为47%。

核心结论

  • 在手术高危前列腺癌患者中,根治性前列腺切除术后5年内进展至临床复发较其他界标点区分度最高,生化复发后12个月内进展至临床复发区分度最高。
  • 这些结果需要前瞻性验证,需进一步研究验证本文发现。

研究设计与样本

  • 多中心回顾性评估1988至2016年间在12家三级转诊中心接受根治性前列腺切除加扩大盆腔淋巴结清扫的3507例高危前列腺癌患者。
  • 采用多变量Cox回归分析评估术后1、3、5、7年内生化复发和临床复发对总生存风险的影响,以及生化复发患者6个月和1、3、5年内进展至临床复发对长期总生存的影响,用Harrell c指数评估区分度。

主要发现

  • 生存者中位随访76个月,5年和10年总生存率分别为94%和81%,5年和10年癌症特异性生存率分别为98%和95%。
  • 时变多变量分析中,生化复发(HR 1.02,95%CI 1.00-1.04)和临床复发(HR 1.05,95%CI 1.03-1.07)为总生存的预测因素(p<0.001)。
  • 术后5年内发生临床复发是预测总生存最具信息量的中间临床终点(c指数0.74)。
  • 生化复发患者中,12个月内进展至临床复发是后续全因死亡风险最具信息量的预测因素。
  • 根治性前列腺切除术后5年内发生生化复发且12个月内进展至临床复发的患者10年总生存率为47%。

局限性

  • 这些结果需要前瞻性验证。
  • 需进一步研究验证本文发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the prolonged natural history of clinically localized, high-risk prostate cancer, there is a need for the identification of intermediate clinical endpoints (ICEs) to predict long-term overall survival (OS). OBJECTIVE: To explore the role of novel potential ICEs based on clinical follow-up to predict long-term survival in patients with high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Overall, 3507 patients treated at 12 tertiary referral centers between 1988 and 2016 were evaluated. INTERVENTION: Radical prostatectomy (RP) with extended pelvic lymph node dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The impact of biochemical recurrence (BCR) and clinical recurrence (CR) within 1, 3, 5, and 7yr after surgery on the risk of OS was evaluated in multivariable Cox regression analyses. In patients with BCR, the impact of progression to CR within 6mo and 1, 3, and 5yr on long-term OS was investigated. Discrimination was assessed using Harrell's c index. RESULTS AND LIMITATIONS: Median follow-up for survivors was 76mo. The 5- and 10-yr OS and cancer-specific survival rates were 94% and 81% versus 98% and 95%, respectively. On a time-varying multivariable analysis, BCR (hazard ratio [HR]: 1.02; 95% confidence interval [CI]: 1.00, 1.04) and CR (HR: 1.05; 95% CI: 1.03-1.07) emerged as predictors of OS (p<0.001). The development of CR within 5yr after surgery was the most informative ICE for predicting OS (c index: 0.74). In patients with BCR, progression to CR within 12mo represented the most informative predictor for the subsequent risk of dying from all causes. Patients who developed BCR within 5yr after RP and progressed to CR within 12mo had a 10-yr OS rate of 47%. These results require prospective validation. CONCLUSIONS: When predicting long-term survival in surgically treated high-risk patients, progression to CR within 5yr of RP confers the highest discrimination with respect to other landmark points. In men experiencing BCR, progression to CR within the subsequent 12mo achieved the highest discrimination. Further studies are needed to validate our findings. PATIENT SUMMARY: We investigated the most informative intermediate clinical endpoints for predicting overall survival (OS). Occurrence of clinical recurrence within 5yr after radical prostatectomy confers the highest discrimination to a model predicting OS.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Martini A, Gandaglia G, Karnes RJ, et al. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31277783. doi:10.1016/j.euo.2018.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。